Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events
Crossref DOI link: https://doi.org/10.1007/s40268-016-0162-8
Published Online: 2016-12-26
Published Print: 2017-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wakabayashi, Hiroki
Inada, Hitoshi
Nishioka, Yosuke
Hasegawa, Masahiro
Nishioka, Kusuki
Sudo, Akihiro
License valid from 2016-12-26